Trikafta (elexacaftor/tezacaftor/ivacaftor) may bring health-related quality of life benefits to people with cystic fibrosis (CF) that go beyond those already reported for breathing, a study found. This expectation stems from a new look by an international team of researchers into data from the two Phase 3 clinical trials that…
News
The bacteria that causes chronic rhinosinusitis — swelling of the nasal cavity and sinuses — in people with cystic fibrosis (CF) are also those that often seed infections in their lungs, which means preventing or treating sinus disease may help better manage the symptoms of CF, a study suggests.
Higher weight in children with cystic fibrosis (CF) at 1 year of age, and increasing weight gain from ages 1 through 5, were correlated significantly with better lung function at age 6, according to an analysis of two large  registries. Current guidelines may need to be updated to encourage…
A measure of lung function called the lung clearance index can detect impaired lung function in children with cystic fibrosis (CF) at earlier ages than standard spirometry, a new study suggests. The study, “Pulmonary exacerbations, airway pathogens, and long-term course of lung clearance index in children…
Getting vaccinated against Coxsackie B viruses (CVB) may help prevent people with cystic fibrosis (CF) from getting ill, according to a new study of CF mouse models. “This study shows that CVB infections are common in the CF population and we provide preclinical evidence that CVB infections are preventable…
Young patients with cystic fibrosis (CF) who have a lung infection caused by Staphylococcus bacteria may have worse lung function and more exacerbations than those who are infected with Pseudomonas bacteria, a Brazilian study has found. The study, “Lower airway microbiota and decreasing lung function in young Brazilian…
Voting is now open for the 2022 Thriving Undergraduate and Thriving Graduate Scholarships — a grant program for students with cystic fibrosis (CF) that is run by AbbVie. This year marks the 30th anniversary of the scholarships program, which annually awards a total of $25,000 each to one…
Treatment with ELX-02 in combination with Kalydeco (ivacaftor) was well-tolerated, but failed to meet efficacy goals in a clinical trial that tested the combo in people with cystic fibrosis (CF) caused by nonsense mutations. Eloxx Pharmaceuticals, the company developing ELX-02, says the lack of efficacy may…
Acne might be a side effect of Trikafta therapy in cystic fibrosis (CF) patients, according to a new case series in the U.S. Trikafta (elexacaftor, tezacaftor, ivacaftor) is a CFTR (cystic fibrosis transmembrane conductance regulator) modulator that helps the defective CFTR protein function more effectively in CF…
Use of Kaftrio (elexacaftor, tezacaftor, and ivacaftor), sold in the U.S. as Trikafta, helped a woman with cystic fibrosis (CF) more easily become pregnant and maintain her health throughout the pregnancy and child’s birth, according to a case report from France. The woman had struggled in a previous pregnancy, due to…
Your CF Community
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.